 |
"We are pleased that we have succeeded in attracting new high quality investors like Wellington Partners in our Series B round. This clearly signals backing from our investor community for the intended merger with Arpida."
Neil Goldsmith
CEO, Evolva
Wellington contact:
Erich Schlick
Developing drugs with genetic chemistry
Evolva uses its proprietary genetic chemistry platform to replicate the ability of nature to create small molecules with exquisite design on an industrial basis. Based on this technology, Evolva has a number of discovery and pre-clinical partnerships which in 2008 generated revenues of about CHF 12 million. Evolva also has an attractive pipeline of drug candiates deriving from this approach – one compound (for renal and cardiovascular disease) entered Phase I beginning of 2009, and two others (an anti-fugal and an anti-viral) are expected to enter Phase I in 2010. The company expects to progress these candidates through phase II proof-of-concept clinical trials over the next 2 to 3 years. The combination of an extraordinary platform and exciting novel products has convinced Wellington Partners to co-lead a Series B round in autumn 2009 together with existing and further new investors. This financing round was also a prerequisite for the planned reverse merger with listed Swiss biotech company Arpida.
First investment: October 2009
Evolva SA
Hagmattstrasse 6
CH-4123 Allschwil
Switzerland
